FDA approves Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers, enhancing treatment options.

The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...

A study reveals that switching from Humira to Amgevita for IBD maintains disease control and offers significant cost savings.

Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price ...

A new biosimilar, SYSA1902, shows comparable efficacy and safety to ustekinumab for treating moderate-to-severe plaque psoriasis, expanding patient options.

HLX02 shows promise as a safe, effective trastuzumab biosimilar for HER2-positive metastatic breast cancer, enhancing treatment access and affordability.

Number 5: A 10-year prospective follow-up of 244 healthy stem cell donors found no new safety concerns with Sandoz’s filgrastim biosimilar, reinforcing its long-term safety for donor mobilization.

A recent Japanese study confirms that switching from originator infliximab to biosimilars maintains remission in patients who ...

After much anticipation, the FDA approves the first interchangeable biosimilar, which is hoped to bring down the high cost of insulin. The FDA has approved Biocon Biologic's Semglee insulin glargine ...